Un homme aux cheveux bruns courts et à la barbe portant une veste de costume bleue et une chemise blanche, debout devant un arrière-plan intérieur flou, représentant des avocats de Chicago spécialisés dans le droit de la propriété intellectuelle.

Shabbi S. Khan

Partenaire

Shabbi Khan serves as a co-chair for the Artificial Intelligence (AI), Automation, and Robotics group within Foley & Lardner’s Manufacturing Sector and is a registered patent attorney and member of the Electronics Practice Group within the firm’s Intellectual Property (IP) department.

Shabbi provides strategic advice on all aspects of IP strategy and enforcement, technology transactions, and licenses. His practice has primarily focused on strategic patent portfolio development, counseling, and management including preparation and prosecution of patent applications, patent infringement analysis, and validity analysis primarily in the fields of AI and machine learning, computer software including cloud and SaaS-based technologies, robotics, medical devices, digital therapeutics, and AI in health care. Shabbi’s technical experience and background, together with his patent prosecution and litigation experience, allows him to quickly understand clients’ technology and products, and prepare high-quality, litigation-ready patents that are aligned with their business objectives.

Shabbi’s practice offers deep experience and a specialty in AI and he helps clients navigate AI-related business and legal issues, including counseling on copyright infringement issues stemming from the use and training of AI models and providing guidance on the operational implementation of AI solutions. As part of his AI practice, Shabbi counsels companies on technology agreements, such as master service agreements, joint development and collaboration agreements, vendor agreements, and technology use and service agreements with a specific eye towards AI related issues and data monetization considerations.

Shabbi also performs buy-side IP due diligence during a merger or acquisition or a financing transaction involving venture capital or private equity. Shabbi also advises technology companies undergoing due diligence or preparing for an upcoming transaction.

Expérience des représentants

  • Advised clients on AI related concerns including the use of generative AI at work
  • Prepared corporate policies relating to the use of AI and prepared checklists and toolkits for companies relating to deployment of AI solutions
  • Conducted legal due diligence for transactions involving an investment in or acquisition of AI technology companies
  • Developed patent portfolios for emerging tech companies in a variety of technical areas including:
  • AI and machine learning
    • Dispositifs médicaux
    • Enterprise Software Solutions
    • Software-related medical device technologies
    • Biotechnology, including data and image processing, analysis, and learning
    •  Gaming
    •  Robotics
    • Computer engineering, architecture, and networking
    • Internet of Things (IoT), devices, and applications
    • Data management and storage
    • Virtual Reality (VR), Augmented Reality (AR), and Mixed Reality (MR) technologies
    • Security, cryptography and encryption
    • Wireless, mobile, and related telecommunications systems

Présentations et publications

  • Author, “European Medtech Companies: Why a U.S. Centric Patent Strategy is Essential for Long-Term Success,” Health Care Law Today (November 12, 2024)
24 octobre 2025 Evénements

21e conférence annuelle sur la propriété intellectuelle

11 juillet 2025 Dans l'actualité

Les avocats de Foley évaluent les considérations critiques en matière de PI pour les entreprises émergentes du secteur des dispositifs médicaux

Les avocats de Foley & Lardner LLP Shabbi Khan, Nate Beaver, Austin Kim et Jeff Simon ont rédigé l'article de Med Device Online intitulé "Critical Considerations For IP & Patents For Emerging Medical Device Companies" (Considérations critiques en matière de propriété intellectuelle et de brevets pour les entreprises émergentes du secteur des dispositifs médicaux).
Un stéthoscope est posé sur des tableaux et des graphiques imprimés présentant des données statistiques et médicales, symbolisant l'intersection du droit de la santé et du droit de la propriété intellectuelle.
April 21, 2025 Health Care Law Today

Table ronde MedTech : ce que l'administration Trump signifie pour les entreprises et les investisseurs

Foley & Lardner LLP a organisé et participé à une table ronde MedTech réunissant des investisseurs et des chefs d'entreprise, notamment des directeurs généraux, des associés, des administrateurs, des responsables de l'innovation, des gestionnaires et associés de fonds d'investissement, ainsi que des directeurs juridiques. Tous ont manifesté un intérêt commun pour comprendre comment ces leaders du secteur MedTech s'adaptent à l'évolution de l'environnement commercial et réglementaire sous la deuxième administration Trump.
Une personne tape sur un ordinateur portable, un stéthoscope étant posé sur le bureau au premier plan, ce qui met en évidence l'intersection du droit de la santé et du droit de la propriété intellectuelle.
November 12, 2024 Health Care Law Today

European Medtech Companies: Why a U.S. Centric Patent Strategy is Essential for Long-Term Success

As European medtech companies look to expand their presence in the U.S. market, understanding the intricacies of U.S. patent law becomes increasingly important.
September 19, 2024 Events

Law School for CFOs

We are excited to host this highly regarded event offered in collaboration with the Boston Chapter of the CFO Leadership Council and presented by Foley & Lardner LLP at our Boston office.
June 12, 2024 In the News

Foley Attorneys Assess AI, Regulatory Risks in Financial Markets

Foley & Lardner LLP partners James Lundy, Peter Fetzer, Chanley Howell, Shabbi Khan, and associate William McCaughey assess artificial intelligence risks relevant to broker-dealers and investment advisers in their LexisNexis article, “Artificial Intelligence (AI) and the SEC: Present and Future Risks.”